BIOMEA FUSION
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
BIOMEA FUSION
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.biomeafusion.com
Total Employee:
11+
Status:
Active
Contact:
(650) 980-9099
Email Addresses:
[email protected]
Total Funding:
56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Epirium Bio
Epirium Bio is a biopharmaceutical company developing a small molecule platform targeting improvements in muscle strength.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Nuvalent
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Stock Details
Investors List
Point Sur Investors
Point Sur Investors investment in Series A - Biomea Fusion
Aisling Capital
Aisling Capital investment in Series A - Biomea Fusion
Logos Capital
Logos Capital investment in Series A - Biomea Fusion
Janus Henderson Investors
Janus Henderson Investors investment in Series A - Biomea Fusion
Rock Springs Capital
Rock Springs Capital investment in Series A - Biomea Fusion
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Biomea Fusion
Boxer Capital
Boxer Capital investment in Series A - Biomea Fusion
RTW Investments LLC
RTW Investments LLC investment in Series A - Biomea Fusion
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.biomeafusion.com Semrush global rank: 1.17 M Semrush visits lastest month: 26.74 K
- Host name: 119.0.153.160.host.secureserver.net
- IP address: 160.153.0.119
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Biomea Fusion"
Biomea Fusion - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (650) 980-9099 Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer …See details»
Investors & Media | Biomea Fusion
Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook. Biomea Fusion Corporate Presentation Q4 2024. Stock Quote. Change Volume 52 Week High 52 Week Low …See details»
QUICK FACTS – Biomea Corporate Overview and Programs
Www.biomeafusion.com . Our Programs . We believe that covalent small molecules have the potential to address the key limitations of existing reversible therapeutics and to treat diseases …See details»
QUICK FACTS Biomea Corporate Overview and Programs - Biomea …
Www.biomeafusion.com BMF-500 Our second development candidate, BMF-500, is a novel third generation covalent inhibitor of FLT3, was discovered and developed in-house at Biomea …See details»
Biomea Fusion, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Biomea Fusion, Inc. of Redwood City, CA. Get the latest business insights from Dun & Bradstreet.See details»
Biomea Fusion, Inc. (BMEA) Company Profile & Facts - Yahoo …
See the company profile for Biomea Fusion, Inc. (BMEA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Biomea Fusion: Contact Details, Revenue, Funding, Employees and …
Biomea Fusion is a biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat metabolic diseases and genetically defined cancers. Their …See details»
Biomea Fusion - LinkedIn
Biomea Fusion | 5,231 followers on LinkedIn. We are creating an entirely new Generation of Precision Medicine against Genetically Defined Diseases. | We are a biopharmaceutical …See details»
Biomea Fusion, Inc. (BMEA) Company Profile & Overview - Stock …
Apr 16, 2021 Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically …See details»
Biomea Fusion Company Profile 2024: Stock …
Biomea Fusion General Information Description. Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to …See details»
Biomea Fusion Company Profile - Office Locations, Competitors
Oct 29, 2024 Biomea Fusion has 2 employees at their 1 location. See insights on Biomea Fusion including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Biomea Fusion Announces Approval of “icovamenib” as …
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and …See details»
Biomea Fusion Announces Approval of “icovamenib” as …
Oct 21, 2024 Biomea Fusion, Inc. Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cellsSee details»
Biomea Fusion Announces Approval of “icovamenib” as ... - BioSpace
Oct 22, 2024 REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to …See details»
Biomea Fusion Raises $56 Million to Bring First Irreversible Menin ...
Jan 6, 2021 For more information, please visit www.biomeafusion.com and follow us on LinkedIn. Contacts. Investor and Media Contact: Ramses Erdtmann Biomea Fusion, Inc. (650) …See details»
Biomea Fusion Moves into New Headquarters and Expands R&D …
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and …See details»
Biomea Fusion Announces FDA and Health Canada Clearance of
Sep 28, 2023 The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with …See details»
Biomea Fusion Announces Approval of “icovamenib” as
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and …See details»
Biomea Fusion Announces Preliminary Data from Ongoing …
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and …See details»